Call Domestic
Call International
Call Health Check
1066
dr-subhash-wangnoo-new
Dr Subhash Wangnoo
Endocrinology & Diabetes Care :
Experience: 31+ Years
Education: MBBS, FRCP, DM, MD(Medicine)
icon
English Hindi
icon
09:00 -09:15 Tue - Fri
Book Appointment
Hospital
Select Date
Loading available days...
Available Slots
Book Appointment
icon
icon icon Call Now
×
About Dr Subhash Wangnoo

Dr. Subhash Wangnoo is a highly experienced Endocrinologist based in Delhi, with an impressive 31 years of practice in the field. He holds multiple qualifications, including MBBS, FRCP, DM, and MD(Med.), which reflect his extensive training and expertise in managing hormonal and metabolic disorders. Dr. Wangnoo is proficient in both English and Hindi, allowing him to effectively communicate with a diverse patient population. His practice is rooted in patient-centered care, focusing on helping individuals with conditions such as diabetes, thyroid issues, and other endocrine disorders. As an esteemed member of the Apollo healthcare network, Dr. Wangnoo is dedicated to providing the highest standard of medical care and is committed to staying current with the latest advancements in endocrinology. His approach is comprehensive, blending clinical expertise with a compassionate understanding of his patients' needs. Whether you're seeking preventive care or management of a chronic condition, Dr. Subhash Wangnoo is equipped to guide you through your healthcare journey.

Read More icon
Ask your query icon
Experience
Medical Officer University Health Centre, B.H.U. Varanasi, May 1981 To September 1981.  
Senior Resident (Registrar) In Endocrinology. IMS, BHU, Varanasi October 1981 To June 1984.
Clinical Attaché in Endocrinology, P.G.I, Chandigarh April 1982 To June 1982.
Pool Officer in Endocrinology, IMS BHU, Varanasi, March 1984 To July 1984.
Lecturer And Head, Department Of Endocrinology, Sher-I-Kashmir Institute Of Medical Sciences, Srinagar Kashmir July 1984 To July 1988
Associate Professor and Head, Department Of Endocrinology, S.K.I.M.S, Srinagar, Kashmir July 1988 To March 1990
Honorary Senior Consultant Endocrinologist, Narinder Mohan Hospital, Mohan Nagar Ghaziabad, April 1990 To January 1992
Senior Consultant Endocrinologist at King Khalid Hospital, Saudi Arabia (Ministry Of Health), February 1992 To December 1994.
Working in Apollo Hospitals since last Assignment

Special interest

Diabetes and Metabolic disorders, Obesity, Thyroid Disease, Reproductive Endorinology, Pituitary Disorders

Memberships

membership-slide-cover
Endocrine Society, USA
membership-slide-cover
American Diabetes Association
membership-slide-cover
Association of American College of Endocrinology
membership-slide-cover
Royal College of Physicians of London, UK
membership-slide-cover
European Association for Study of Diabetes
membership-slide-cover
Diabetes Technology and Therapeutics, USA  
membership-slide-cover
International Diabetes Federation 8. Association of Physicians of India
membership-slide-cover
Endocrine Society, India
membership-slide-cover
Research Society for Study of Diabetes in India
membership-slide-cover
Indian Thyroid Society
membership-slide-cover
South Asian Association for Regional Co-operation Diabetes Society
membership-slide-cover
Indian Menopause Society
membership-slide-cover
Diabetes India

Awards & Achievements

Honorary Fellowship of the Royal College of Physicians, London (FRCP), 2011
awards-icon
Established and currently heading the Apollo Centre for Obesity, Diabetes and Endocrinology (ACODE)
awards-icon
Instrumental in establishing the Department of Endocrinology, Diabetes, and Metabolic Medicine at Sher-I-Kashmir Institute of Medical Sciences, Srinagar, J&K
awards-icon
Former Honorary Endocrinologist to the President of India
awards-icon
Actively involved in teaching and training DNB Endocrinology students for over 8 years, the only Apollo hospital with a DNB Endocrinology program
awards-icon
Member of various advisory boards and national & international academic guideline-forming bodies
awards-icon
Invited faculty at various national and international conferences
awards-icon

Research & Publications

01
Wangnoo SK. Initiating insulin therapy in children and adolescents with type I diabetes mellitus. Indian J Endocrinol  Meab.2015 Apr;19(suppl I):S68-70.  
02
Jindal R,Siddiqui MA, Gupta N, Wangnoo SK. Prevalence of glucose intolerance at 6 weeks postpartum in Indian women with gestational diabetes mellitus, Diabetes Metab Syndr.2015 Jul-Sep;9(3):143-6.
03
Tandon N, Kalra S, Balhara YP, Baruah MP, Chadha M, chandalia HB, Chowdhury S, Jothydev K, Kumar PK, V MS, Mithal A, Modi S, Pitale S, Sahay R, Shukla R, Sundram A, Unnikrishnan AG, Wangnoo SK. Forum for Injection Technique(FIT), India: The Indian  recommendations 2.0, for best practice in Insulin Injection Technique, 2015. Indian K Endocrinol Metab.2015 May-Jun;19(3):317-31.            
04
Wangnoo SK, Chowdhury S, Rao PV. Treating to target in type 2 diabetes: the BEGIN trial programme. J Assoc Physicians India. 2014 Jan;62(I Suppl):21-6.
05
Mohan V, Shah SN, Joshi SR, Seshiah V, Sahay BK, Banerjee S, Wangnoo SK, Kumar A, Kalra S, Unnilrishnan AG, Sharma SK, Rao PV, Akhtar S, Shety RV, Das AK; DiabCare India 2011 Study Group. Current status of management, control, complications and psychosocial aspects of patients with diabetes in India: Results from the DiabCare India 2011 Study. Indian J Endocrinol Metab. 2014 May:m18(3):370-8.             
06
Kesavadev J, Sadikot S, Wangnoo S, Kannampilly J, Saboo B, Aravind SR, Kalra S, Makkar BM, Maji D, Saikia M, Anjana RM, Rajput R, Singh SK, Shah S, Dhruv U, Vishwanathan V. Consensus guidelines for glycemic monitoring in  type I/type 2 and GDM. Diabetes Metab syndr.2014Jul-Sep;8(3):187-95.            
07
Wangnoo SK, Sethi B, Sahay RK, John M, Ghosal  S, Sharma SK. Treat-to-target trials in diabetes. Indian J Endocrinol Metab.2014Mar;18(2):166-74.
08
Wangnoo SK, Ghosal S, Akhtar S, Shetty R, Tripathi S. Wangnoo SK, Ghosal S, Akhtar S, Shetty R, Tripathi S. Clinical experience of switching from glargine or neutal protamine hagedorn insulin to insulin detemir in type 2 diabetes:Observations from the Indian cohort in the AI chieve study. Indian J Endocrinol Metab, 2014 Sep;18(5):715-20.           
09
Wangnoo SK, Sethi B, Sahay RK, John M, Ghosal S, Sharma SK. Treat-to-target trials in diabetes. Indian J Endocinol Metab.2014 Mar;18(2):166-74.            
10
Radhika Jindal, Ayesha Ahmad, Mohammad Asim Siddiqui, Inderpal Singh Kochar, Subhash Kumar Wangnoo. Novel mutation .597_598dup in exon 5 of ABCC8 gene causing congenital hyperinsulinism. Diabetes Metb syndr.2014 Jan-Mar;8(1):45-7.
11
Wangnoo SK, Bader G, Gawai A, Singh S. Effectiveness and Tolerability of Vildagliptin in Indian Patients with Type 2 Diabetes Mellitus: Results From Edge-A Renal-World Obervational Study IJCP.2013;24(6):537-42. 
12
Jindal R, gupta N, Siddiqui MA, Wangnoo SK, Post-Prandial Hyperglycemia.JIACM.2013;14(3-4);242-246.
13
Mathieu C, Barnett AH, Brath H, Conget I, de Castro JJ, Goke R, Marquez Rodriguez E, Nilson PM, Pagkalos E, Penfornia A, Schaper NC, Wangnoo SK, Kothny W, Bader G. Effectiveness and tolerability of second-line therapy with vildagliptin vs. other oral agents in type 2 diabetes: a real-life worldwide observational study (EDGE). Int J Clin pract.2013 oct; 67(10):947-56.
14
Wangnoo SK, Maji D, Das AK, Rao PV, Moses A, Sethi B, Unnikrishnan AG, Kalra S, Balaji V, Bantwal G, Kesavadev J, Jain SM, Dharmalingam M. Barries and solutions to diabetes management: An Indian perspective. Indian J Endocinol Metab.2013 Jul;17(4):594-601.          
15
Niti Agarwal, SK Wangnoo, Asim Siddiqui, Mukul Gupta. primary thyroid Lymphoma: A Series of Two Cases and Review of Literature. JAPI 2013;(61)496-498.
16
Gokulnath, Sahay M, Kalra S, Vishwanathan V, Zargar AH, Talwalkar PG, Wangoo SK, Maji D, Kumar GV, Sharma RK, Chafekar D, Mohan B, Bantwal G, Bansali A, Sahni JS. Protocol of an observation al study to evaluate diabetic nephropathy through detection of mucroalbuminuria in Indian patients. Indian J Endocrinol Metab. 2013 May;17(3):496-504.
17
Zubair Ahmed, Jamal Ahmad, Abida Malik, Mohammad Asim Siddiqui, Sibhash Kumar Wangnoo, Cathepsin-d, Adiponection, TNF-alpha, IL-6 and hsCRP plasma levesl in subjects with diabetic foot and possible correlation with clinical variables: a multicentric study. Ahmad J, Zubair M, Malik A, Siddiqui MA, Wangnoo SK. Foot (Ednib).2012 Sep;22(3):1949-9. EPup 2012 May 3.
18
Unnikrishnan AG, Wangnoo SK, Joshi SR, Banerjee S, Kumar A, Kalra S, channabasavaiah R, Shetty R.Physician perceptions and practices in management of diabetes in India: Results from the IMPROVE Control program. Indian K Endocrinol Metab. 2012 Dec;16(suppl 2):S428-9.
19
Jindal R, Ahmad A, Siddiqui MA, Wangnoo SK. What the future holds for gliptins. Indian J Endocrinol Metab.2012 Dec;16(suppl 2): S242-4.
20
Ahmad A, Siddiqui Ma, Goyal A, Wangnoo SK. BMJ Case Rep.2012 Jul 18:2012.
21
Mohan v, Unnikrishnan R, Thomas N, Bhansali A, Wangnoo SK, Thomas K. Pneumococcal inections and immunization in diabetic patients. J Postguard Med.2011 Jan-Mar;57(1):78-81.
22
M. Siddiqui, M. Gupta, V. KAul, S.K. Wangnoo . Improvement in Glycemic control daily injections in diabetes in pregnancy. Diabetes Technology and Therapeutics Volume 13, Number 2, 2011;P273-274.
23
Mohammad Siddiqui, Mukul Gupta, Subhash Wangnoo & Jamal Ahmad. Safety profile of Vidagliptin in clinical pratice: 2-year data from 2 Teritary hospitals. Endocine Abstracts (2011)25P128.
24
Mohammad Asim Siddiqui, Ayesha Ahmad, Mukul Gupta, Nitin Guptam Subhash Kumar Wangnoo. Prevalence of Abnormal Metabolic Parameters in Overweight Non-Diabetic children. Endocr Rev June 2011;32, P3-421.
25
Mukul Gupta, Mohammad Asim Siddiqui, Ayesha Ahmad, Mukul Gupta , Nitin Gupta, Subhash Kumar Wangnoo. Durability of Effects of Exenatide Treatment of Glycemic Control, Body Weight, hsCRP, Lipid Concentrations and Bone Mineral Density. Endocr Rev, Vol.32:P3-492.
26
Mohammad Asim Siddiqui, Mukul gupta, Nitin Gupta, Subhash Kumar Wangnoo. Improvements in Metabolic Parameters along with Glycemic Status in Newly Diagnosed Obese North Indian Type 2 Diabetes on Liraglutide Addition to Metfromin Monotherapy. Daibetes July 2011 60; A6092292 PO.
27
Mohammad Asim Siddiqui, SK Wangnoo. Metabolic Phenotype in brother's of women with polycystic ovarian syndrome. Endocrine Abstracts.P165(2010). Vol21.
28
M Gupta, MA Siddiqui, SK Wangnoo. Risk Awareness of Conversion of Gestational Diabetes Mellitus into Diabetes among women with Previous History of GDM and Treating General Practioners Endocrine Reviews, Supplement 1, June 2010, 31(3); S1443.
29
M.A. Siddiqui, M gupta, SK Wangnoo, J Ahmad, Clinical And Metabolic Heterogenity in Obese and Lean Women With Polycystic Ovarian Disease. Endocine Reviews, Supplement 1, June 2010, 31(3):S2108.
30
S.k.Wangnoo, M.A. Siddiqui, M. Gupta. Effect of Long-Acting Obstructive Sandostatin Analogs On Blood Glucose Profiles in Patient with Acromegaly. Endocine Reviews, Supplement 1, June 2010, 31(3):S2256.
31
S.K. Wangnoo, M.A. Siddiqui, M. gupta, M.S.Kanwar. Obstructive Sleep Apnoea and metabolic abnormalities in type 2 diabetes, Diabetologia (2010)53:(suppl I)S1-S556.
32
N Shamra , H. Dua, MA Siddiqui, M Gupta, SK Wangnoo. Prevalence of 25 Hydroxyvitamin D Deficiency in Newly Diagnosed Multiple Myeloma patients in a tertiary Care setting. Osteoporosis International (2010). Volume 21. Supplements 5.
33
Misra A, Chowbey P, Makkar BM, Vikram NK, Wasir JS, Chadha D, Joshi SR, Sadikot S, Gupta R, Gulati S, Munjal YP; consensus Group. Consensus statement  for diagnosis of obesity, abdominal obesity and the metabolic syndorme for Asian Indians and recommendations for physicial activity, medical and surgical management. J Assoc Physician India.2009 Feb; 57:163-70.
34
Jadzinsky M, Pftitzner A, Paz-Pachoo E, XU Z, Allen E, Chen R; CV181-039 Investigators. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in  patients with type 2 diabetes compared with either monotherpay: a randomized controlled trial. Diabetes obes Metab. 2009Jun;11(6):611-22.
35
Govalkar RM, Wangnoo SK. Localized genital kaposi sarcoma. ANN Saudi Med.1994 Nov;14(6):517-8. 36. Koul R, Saxena R, Wangnoo S. Myelomyopathy and throtoxicosis. J Assoc Physician India. 1989 Nov 37(11):721 Siddiqui MA, Wangnoo SK, Selective IgG subclass antibody response to insulin in diabetic receiving animal insulin replacement therapy. Int Arch Allergy Appl Immunol. 1989;89(1):49-53.

Doctor Location

Apollo Hospitals, Delhi

FAQs

Q: Where does Dr. Subhash Wangnoo practice?
Dr. Subhash Wangnoo's practice is located at Apollo Hospitals, Delhi. This hospital offers comprehensive healthcare services and advanced medical expertise.
Q: Who is Dr. Subhash Wangnoo?
Dr Subhash Wangnoo is a renowned Endocrinologist with over 31 years of experience. He practices in Delhi at Apollo Hospitals Delhi. Dr Subhash Wangnoo holds a degree in MBBS, FRCP, DM, MD(Medicine). He provides treatments including Insulin Therapy, Thyroid Hormone Replacement, Bone Density Treatments. He specializes in treating conditions like Diabetes Mellitus, Thyroid Disorders, Osteoporosis.
Q: What is Dr. Subhash Wangnoo's specialization?
Dr Subhash Wangnoo specializes in Endocrinology. He has expertise in treating conditions such as Diabetes Mellitus, Thyroid Disorders, Osteoporosis. His key treatments include Insulin Therapy, Thyroid Hormone Replacement, Bone Density Treatments.
Q: What are Dr. Subhash Wangnoo's medical qualifications?
Dr Subhash Wangnoo holds MBBS, FRCP, DM, MD(Medicine), reflecting his comprehensive education in the field of Endocrinology.
Q: What is Dr. Subhash Wangnoo's experience?
Dr. Subhash Wangnoo has 31 years of experience in endocrinology.
Q: Why do patients consult Dr. Subhash Wangnoo?
Patients seek Dr. Subhash Wangnoo's expertise for conditions including lactation counseling, hypertension treatment, and thyroid swelling. For a complete list of his areas of specialization, please refer to his profile.
Q: What is patient feedback on Dr. Subhash Wangnoo?
Dr. Subhash Wangnoo has received positive feedback from 10 patients, including 9 detailed reviews. To access these testimonials, please contact the hospital directly.
Q: Who is an endocrinologist?
Endocrinologists are medical doctors specializing in the diagnosis and treatment of endocrine system disorders. Their expertise encompasses hormone-related illnesses affecting glands like the thyroid, pituitary, and pancreas.
Q: What symptoms necessitate an endocrinology consultation?
Consult an endocrinologist if you experience symptoms suggestive of hormonal imbalances, such as unexplained weight fluctuations, acne, hirsutism (in women), infertility, fatigue, significant hair loss, intolerance to temperature changes, voice alterations, and other related issues. These symptoms may indicate underlying endocrine disorders requiring specialist care.
Q: What conditions are treated by an endocrinologist?
Endocrinologists manage various hormonal disorders, including hypothyroidism, hyperthyroidism, insulin imbalances (diabetes), gigantism, dwarfism, Cushing's syndrome, pituitary gland dysfunction, polycystic ovary syndrome (PCOD), and infertility.
VIEW ALL
icon
Ask your query
icon Call Now
Book Appointment icon
image image
Request a Callback

Find Hospital

Find Cardiologist

Find Neurologist

Find Orthopedician

Find Oncologist

Find Gastroenterologist

Find Transplant Surgeon

Find ENT Specialist

Find Pulmonologist

Find Dentist

Find Pediatric

Find Dermatologist

Find Urologist

Find Diabetologist

Find Gynecologist

Find General Physician

Find Psychologist

Find General Surgeon

Request A Call Back
Request Type